StockData
Humacyte, Inc. logo

Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$0.50−0.04 (-7.27%)

Close on Nov 17, 2026Market cap $139.18MP/E –Yield –

Humacyte net income

Net income is the profit left for shareholders after every expense, interest and tax.

Humacyte's net income for the twelve months ending Jun 30, 2026 was -$96.74M. For fiscal 2025 it was -$40.83M. The highest annual figure on record is -$11.97M in fiscal 2022.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$40.83M–
FY2024Dec 31, 2024-$148.70M–
FY2023Dec 31, 2023-$110.78M–
FY2022Dec 31, 2022-$11.97M–
FY2021Dec 31, 2021-$26.48M–
FY2020Dec 31, 2020-$66.52M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$36.80M–
Q1 FY2026Mar 31, 2026-$17.62M-145.0%
Q4 FY2025Dec 31, 2025-$24.80M–
Q3 FY2025Sep 30, 2025-$17.51M–
Q2 FY2025Jun 30, 2025-$37.66M–
Q1 FY2025Mar 31, 2025$39.14M–
Q4 FY2024Dec 31, 2024-$20.94M–
Q3 FY2024Sep 30, 2024-$39.20M–
Q2 FY2024Jun 30, 2024-$56.66M–
Q1 FY2024Mar 31, 2024-$31.90M–
Q4 FY2023Dec 31, 2023-$25.11M–
Q3 FY2023Sep 30, 2023-$26.00M–
Q2 FY2023Jun 30, 2023-$22.71M-161.6%
Q1 FY2023Mar 31, 2023-$36.97M–
Q4 FY2022Dec 31, 2022-$3.72M-108.7%
Q3 FY2022Sep 30, 2022-$25.28M–
Q2 FY2022Jun 30, 2022$36.87M–
Q1 FY2022Mar 31, 2022-$19.83M–
Q4 FY2021Dec 31, 2021$42.59M–
Q3 FY2021Sep 30, 2021-$31.56M–
Q2 FY2021Jun 30, 2021-$17.20M–
Q1 FY2021Mar 31, 2021-$20.30M–
Q4 FY2020Dec 31, 2020-$16.21M–
Q3 FY2020Sep 30, 2020-$17.76M–
Q2 FY2020Jun 30, 2020-$14.88M–
Q1 FY2020Mar 31, 2020-$17.67M–

More Humacyte figures

See a number that looks wrong?